Glaxo In $350 Mn Cancer Deal With Biotech Specialist

Glaxo In $350 Mn Cancer Deal With Biotech Specialist

Glaxo In $350 Mn Cancer Deal With Biotech Specialist
Biotechnology News

British pharmaceuticals giant GlaxoSmithKline has agreed a $350-million deal with Adaptimmune to help develop and sell the biotechnology firm's cancer drugs, the companies said on Monday. Adaptimmune announced in a statement that it has entered a "strategic cancer immunotherapy collaboration" with GSK to "develop and commercialise novel cell-based therapies" in its lead clinical cancer programme. The biotech firm, which is based in Oxford, southern England and Philadelphia, has had success in trials in using T-cells, the heavy weaponry of the immune system, to target cancer cells. The statement added that trials in Adaptimmune's lead programme, in multiple myeloma, melanoma, sarcoma and ovarian cancer in the United States, are generating "encouraging" results.

Source